Literature DB >> 31058559

Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway.

Sneha Priya Aravinth1,2, Sakthi Rajendran1,2, Yating Li1,2, Meihui Wu1,2, Anna Hiu Yi Wong1,2, Herbert Schwarz1,2.   

Abstract

CD137 is a potent co-stimulatory molecule on activated T cells, and its ligand (CD137L) is expressed on antigen presenting cells (APC). Ectopic expression of CD137 has been identified on Hodgkin Reed-Sternberg (HRS) cells, the malignant cells in Hodgkin Lymphoma (HL), and CD137 on HRS cells was found to support growth of HRS cells and escape from immune surveillance. HRS cells are mostly derived from B cells, which poses the question of how B cells acquire ectopic CD137 expression during the transformation process. HL is associated with Epstein-Barr virus (EBV) infection. We show that the EBV latent membrane protein 1 (LMP1) induces expression of CD137 in HRS cell lines. In a HL tissue microarray, 96% of the CD137-positive HL cases stained positive for LMP1. LMP1 utilizes the PI3K-AKT-mTOR pathway for inducing CD137 expression. These findings support the role of EBV in HL pathogenesis.

Entities:  

Keywords:  CD137; EBV; Hodgkin lymphoma; LMP1

Mesh:

Substances:

Year:  2019        PMID: 31058559     DOI: 10.1080/10428194.2019.1607330

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.

Authors:  Mukul Prasad; Sashigala Ponnalagu; Qun Zeng; Khang Luu; Si Min Lang; Hiu Yi Wong; Man Si Cheng; Meihui Wu; Karthik Mallilankaraman; Radoslaw Mikolaj Sobota; Yan Ting Lim; Loo Chien Wang; Chuan Keng Goh; Kai Xun Joshua Tay; Kwok Seng Loh; Cheng-I Wang; Wen-Hsien Lee; Boon Cher Goh; Chwee Ming Lim; Herbert Schwarz
Journal:  Cancer Immunol Immunother       Date:  2022-03-17       Impact factor: 6.630

2.  Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.

Authors:  Jillian A Bristol; Joshua Brand; Makoto Ohashi; Mark R Eichelberg; Alejandro Casco; Scott E Nelson; Mitchell Hayes; James C Romero-Masters; Dana C Baiu; Jenny E Gumperz; Eric C Johannsen; Huy Q Dinh; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2022-04-26       Impact factor: 7.464

3.  Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells.

Authors:  Sakthi Rajendran; Yating Li; Evelyn Ngoh; Hiu Yi Wong; Man Si Cheng; Cheng-I Wang; Herbert Schwarz
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

4.  Destroy, what destroys you.

Authors:  Khang Luu; Emily Nickles; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2019-11-03       Impact factor: 8.110

5.  Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting.

Authors:  Kang Yi Lee; Hiu Yi Wong; Qun Zeng; Jia Le Lin; Man Si Cheng; Chik Hong Kuick; Kenneth Tou En Chang; Amos Hong Pheng Loh; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2021-02-04       Impact factor: 8.110

6.  Elevated soluble 4-1BB is associated with serum markers of hepatitis B virus in patients with chronic hepatitis B.

Authors:  Meng-Ru Zhan; Xiu-Zhu Gao; Chang Wang; Fei Peng; Xiao-Mei Wang; Hong-Qin Xu; Jun-Qi Niu
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

Review 7.  Targeting 4-1BB for tumor immunotherapy from bench to bedside.

Authors:  Ya-Tao Wang; Wei-Dong Ji; Hong-Mei Jiao; Ang Lu; Kun-Feng Chen; Qi-Bing Liu
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

8.  EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.

Authors:  Chunrong Li; James C Romero-Masters; Shane Huebner; Makoto Ohashi; Mitchell Hayes; Jillian A Bristol; Scott E Nelson; Mark R Eichelberg; Nicholas Van Sciver; Erik A Ranheim; Rona S Scott; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2020-06-15       Impact factor: 6.823

Review 9.  The role of trogocytosis in immune surveillance of Hodgkin lymphoma.

Authors:  Qun Zeng; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2020-06-17       Impact factor: 8.110

Review 10.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.